A novel IRAK4 inhibitor, CA−4948, has shown promising clinical activity in individuals with MDS and AML, particularly those with splicing factor mutations, although has yet to be studied in CH [76]. The gene discussed is SLU7; the disease is myelodysplastic syndrome.